sur POXEL (EPA:POXEL)
POXEL announces a significant increase in its sales in the second quarter of 2024
Biopharmaceutical company POXEL SA reported a 62% increase in sales of TWYMEEG® in Japan for the second quarter of 2024 compared to the previous quarter. Total sales for the first half of 2024 reached EUR 1.16 million, up from EUR 955 thousand for the corresponding period in 2023.
The Company is currently finalizing exclusive discussions with an investor to monetize royalties from sales of TWYMEEG® in Japan. POXEL's cash position stood at €2.8 million as of June 30, 2024, which is considered sufficient until the closing of this transaction.
In addition, the results of the TWINKLE post-marketing study confirm the positive profile of TWYMEEG® for patients with type 2 diabetes and renal impairment. These results should allow Sumitomo Pharma to discuss a revision of the drug's leaflet with the Japanese authorities.
In parallel, POXEL is continuing negotiations with several partners for its other products, notably PXL065 and PXL770, in order to diversify its sources of revenue and strengthen its position on the market for rare metabolic diseases.
R. H.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de POXEL